Disrupting cancer cell division: How tumour treating fields are changing oncology

Tumour Treating Fields (TTFields) present a completely different approach to cancer therapy, involving alternating electric fields that, when applied to specific frequencies, can disrupt cancer cell division.

At ASCO 2025 in Chicago, web editor Nicole Raleigh spoke with Dr Vincent Picozzi, MD, MMM, medical oncologist and investigator in Novocure’s PANOVA-3 trial, who discussed the company’s growth and late-breaking data on the positive Phase 3 results for pancreatic cancer, evaluating the use of TTFields with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).

Tune into the conversation for updates direct from the Congress, and be sure to catch our other #ASCO25 content here.